All In Biotech

Drug Trial Radar · NCT00174915

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.

Last checked: Nov 20, 2026Latest source record: Feb 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,072 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,072

Actual

Start

Feb 2003

Primary completion

Apr 2004

Study completion Apr 2004

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout.

Conditions

  • Gout

Interventions

  • FebuxostatDrug

    Febuxostat 80 mg, orally, once daily for up to 28 weeks.

  • FebuxostatDrug

    Febuxostat 120 mg, orally, once daily for up to 28 weeks.

  • FebuxostatDrug

    Febuxostat 240 mg, orally, once daily for up to 28 weeks.

  • AllopurinolDrug

    Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.

  • PlaceboDrug

    Placebo, orally, once daily for up to 28 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL).Time frame: Last 3 visits (any last 3 visits up to week 28)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.